Glucose variability in older adults with Type 1 diabetes

  • Research type

    Research Study

  • Full title

    Feasibility study: An investigation of frailty and glycaemic control in older adults with Type 1 diabetes mellitus

  • IRAS ID

    295171

  • Contact name

    Jonathan Golding

  • Contact email

    jonathan.golding1@nhs.net

  • Sponsor organisation

    University Hospitals Sussex

  • ISRCTN Number

    ISRCTN30513341

  • Duration of Study in the UK

    0 years, 9 months, 2 days

  • Research summary

    This study will look at people over the age of 65 with Type 1 diabetes (T1DM). This pilot study will test the procedures for a larger study which will look at whether age-related changes can impact on glucose control.

    People with T1DM require insulin injections to keep blood glucose levels as close to normal as possible. High or low blood glucose levels can cause unpleasant symptoms and longer term health problems. As people get older, changes in weight, appetite, physical activity and memory can affect the amount of insulin someone needs and/or their ability to look after their own T1DM. Collectively these changes are known as frailty. A particular problem is low blood glucose levels (hypoglycaemia). Hypoglycaemia is dangerous, increasing the risk of falls, hospital admissions and even death. Symptoms of hypoglycaemia will usually trigger the patient to take in sugar and modify their insulin. Older adults may lose these symptoms meaning these episodes may go unrecognised.

    We suspect that older people with more changes associated with frailty are likely to have more fluctuations in their glucose levels and be at greater risk of hypoglycaemia. This has not yet been proven in a trial.

    this study, a urine test will be used to assess insulin production. Frailty assessment will involve: quality of life and physical activity questionnaires; and physical tests such as grip strength and walking speed to assess for frailty. A continuous glucose monitor (a small device attached to the skin) will then be applied and worn by the participant for 10 days. During this time the participant will carry on monitoring their glucose levels as usual and adjusting their insulin doses. The participant will not see the data. Data will be analysed to assess whether age related changes affect glucose control.

  • REC name

    South West - Frenchay Research Ethics Committee

  • REC reference

    22/SW/0016

  • Date of REC Opinion

    30 Mar 2022

  • REC opinion

    Further Information Favourable Opinion